We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

50 hedge funds and large institutions have $974M invested in Arcutis Biotherapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

85.82% more ownership

Funds ownership: 0% → 85.82% (+86%)

Holders
50
Holders Change
+50
Holders Change %
–
% of All Funds
1.1%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
50
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
+$283M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$154M
3
O
OrbiMed
New York
+$126M
4
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$107M
5
VC
Vivo Capital
California
+$45.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
1
Frazier Management
Washington
$314M +$283M +10,542,790 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$170M +$154M +5,713,343 New
O
3
OrbiMed
New York
$139M +$126M +4,673,850 New
BCLSI
4
Bain Capital Life Sciences Investors
Massachusetts
$119M +$107M +3,979,292 New
VC
5
Vivo Capital
California
$50.3M +$45.3M +1,686,527 New
RCM
6
RA Capital Management
Massachusetts
$34.7M +$31.3M +1,165,184 New
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$29.2M +$26.3M +980,614 New
BlackRock
8
BlackRock
New York
$25.8M +$23.2M +865,309 New
OFM
9
Omega Fund Management
Massachusetts
$25.2M +$22.7M +844,680 New
Wells Fargo
10
Wells Fargo
California
$12.3M +$11.1M +413,771 New
PC
11
Polar Capital
United Kingdom
$11.2M +$10.1M +375,000 New
Ameriprise
12
Ameriprise
Minnesota
$7.58M +$6.84M +254,439 New
Goldman Sachs
13
Goldman Sachs
New York
$5.95M +$5.36M +199,630 New
Vanguard Group
14
Vanguard Group
Pennsylvania
$5.23M +$4.71M +175,408 New
State Street
15
State Street
Massachusetts
$4.99M +$4.5M +167,558 New
Northern Trust
16
Northern Trust
Illinois
$3.23M +$2.91M +108,459 New
AllianceBernstein
17
AllianceBernstein
Tennessee
$2.05M +$1.85M +68,836 New
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.8M +$1.62M +60,380 New
Citadel Advisors
19
Citadel Advisors
Florida
$1.66M +$1.49M +55,565 New
LCM
20
Laurion Capital Management
New York
$1.49M +$1.34M +50,000 New
MWNA
21
Marshall Wace North America
New York
$1.23M +$1.11M +41,315 New
N
22
Nuveen
North Carolina
$1.16M +$1.05M +38,896 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$718K +$647K +24,084 New
CCM
24
CAAS Capital Management
New York
$668K +$602K +22,413 New
Charles Schwab
25
Charles Schwab
California
$657K +$592K +22,021 New
1
2

ARQT Hedge Fund Activity: Q1 2020 in Review

50 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2020, worth a combined $974M.

Buyers outnumbered sellers: 50 funds opened new ARQT positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Frazier Management, opening a new position worth an estimated $283M.

  • 50 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2020, up from 0 in Q4 2019.
  • Funds reported $974M of Arcutis Biotherapeutics stock for Q1 2020.
  • 50 funds opened new Arcutis Biotherapeutics positions in Q1 2020 and 0 closed out, a net change of +50 holders.
  • The largest Arcutis Biotherapeutics buyer in Q1 2020 was Frazier Management, an estimated $283M added.

Based on aggregated 13F filings for Q1 2020.